The Week

Johnson & Johnson (JNJ) rose 0.46% this week to $271.22, against a 1.21% gain for the S&P 500, underperforming the benchmark by roughly 0.75 percentage points. The week was choppy before a late lift: Monday opened at $271.74 and slid to $269.47, Tuesday touched the weekly low of $265.04, Wednesday ranged between $266.50 and $272.14, Thursday hit the weekly high of $275.23, and Friday settled at $271.22. Average daily turnover was about 5.4 million shares, roughly 16.94% below the 60-day median, pointing to lighter participation.

Key Events

The company news flow this week ran on two main rails: psychiatry and multiple myeloma. On Monday, Phase 3 data showed Caplyta (lumateperone) improved bipolar I mania symptoms by Week 3, and the stock gained the next day. CHMP then backed expanded use of teclistamab, while DePuy Synthes showcased next-generation trauma devices at the Orthopaedic Trauma Association annual meeting. From Wednesday, the blood-cancer line took over: a MajesTEC-3 model-based analysis projected near-general-population mortality risk for the Tecvayli-Darzalex combination in early relapsed myeloma. On Friday, J&J reported that a single infusion of Carvykti produced five-year treatment-free remission in 50% of patients with early-line relapsed/refractory multiple myeloma, and that TREMFYA (guselkumab) became the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in an axial psoriatic arthritis study.

Analyst Ratings

Across 24 institutions covering the stock, 11 rate it buy, 5 rate it overweight, 6 rate it hold, 1 rate it sell, and 1 has no opinion. The consensus rating is buy, with a consensus target of $277.91, about 2.47% above the spot price. The target range is wide: $190.00 to $320.00, implying roughly 30% downside at the low end and roughly 18% upside at the high end. J&J ranks 5th among 203 names in its industry, near the top of the group.

The Week Ahead

The next direct company event is J&J’s fiscal Q3 2026 earnings on 13 October before the open. Consensus estimates point to EPS of about $2.07 and revenue of about $25.3 billion. On the macro side, the Dallas Fed manufacturing business activity index arrives on 28 September, followed on 29 September by FHFA house prices, the Case-Shiller 20-city home price index, JOLTS job openings, and consumer confidence. These will shape risk appetite across healthcare and the broader tape.

In Short

The week was packed with clinical reads on Caplyta and Carvykti, which helps explain some of the attention on the name, but the stock only added 0.46% and lagged the S&P 500 by about 0.75 percentage points. Light volume reinforces the sense that the market has not rushed to price in this news flow. The analyst picture adds another layer of tension: the consensus rating skews positive and the target sits above spot, but the target range is unusually wide, meaning views on valuation and pipeline timing diverge sharply. Valuation carries its own push and pull: a static P/E of about 31.1 times is not cheap, while a dividend yield of about 1.95% keeps a defensive profile within pharma. The key test ahead is whether Q3 results can match consensus, and how commercial and regulatory progress on Caplyta and Carvykti develops.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.